


Insilico Medicine secures \$110 M Series E financing to advance AI-driven drug discovery innovation

13 March 2025 | News

Funds raised in this round will be directed to advance Insilico's innovative drug pipeline and AI platform developments



Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has successfully secured a \$110 million Series E financing led by a private equity fund of Value Partners Group, one of Asia's largest independent asset management firms, with strong participation from industry- and technology-focused new investors, as well as continued support from global existing backers.

The funds raised in this round will be directed to advance Insilico's innovative drug pipeline and AI platform developments. On one side, resources will focus on refining AI models and algorithms, alongside updates and expansions to its state-of-the-art automatic lab to further automate and streamline R&D processes.

On the other side, Insilico will focus on advancing the clinical validation of its flagship candidate for idiopathic pulmonary fibrosis treatment and accelerating the exploration of other independently developed and co-developed drug pipelines, driving impactful innovations in healthcare.

Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine said, "The funds raised will accelerate the advancement of our drug pipeline and AI platform, further solidifying Insilico's leadership in this rapidly evolving sector. We remain dedicated

to our mission of extending productive longevity to people and are proud to be at the forefront of innovation in healthcare."

Since its previous financing round, Insilico has achieved substantial progress in both the development of AI platform and drug discovery pipeline and has showcased the ability of its proprietary AI-driven platform to significantly reduce costs and enhance efficiency in the early stages of drug discovery.

To date, Insilico has rapidly built a wholly-owned drug discovery portfolio of 30 assets driven by its advanced Pharma.AI platform, with 10 of these assets receiving IND clearance. Among them, the most advanced candidate, Rentosertib (formerly known as ISM001-055), developed for treating idiopathic pulmonary fibrosis (IPF), has progressed through multiple clinical studies with encouraging results.

In addition, Insilico has established a sustainable revenue stream through its business model centered on out-licensing deals for its pipelines. The company has secured four pipeline out-licensing agreements with Fosun Pharma, Exelixis, and Menarini, collectively valued at over \$2.1 billion. Concurrently, Insilico has initiated multiple drug discovery and development collaborations with industry partners, including Sanofi, Saudi Aramco, Therasid Bioscience and others, with the collected value of over \$1.4 billion.